This group includes the CD30+ T-cell lymphoproliferative disorders which, according to the 2022 5th edition of the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC), include lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma (ALCL), and borderline lesions [3,4,5,6]. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.